DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Uterine
Leiomyoma (Uterine Fibroids) – Pipeline Review, H2 2016” report
to their offering.
This report provides comprehensive information on the therapeutic
development for Uterine Leiomyoma, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for Uterine
Leiomyoma and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Key Topics Covered:
- Uterine Leiomyoma Overview
- Therapeutics Development
- Pipeline Products for Uterine Leiomyoma – Overview
- Pipeline Products for Uterine Leiomyoma – Comparative Analysis
- Uterine Leiomyoma – Therapeutics under Development by Companies
Uterine Leiomyoma – Therapeutics under Investigation by
- Uterine Leiomyoma Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Uterine Leiomyoma – Products under Development by Companies
Uterine Leiomyoma – Products under Investigation by
- Uterine Leiomyoma – Companies Involved in Therapeutics Development
- AbbVie Inc.
- Addex Therapeutics Ltd
- Bayer AG
- BioSpecifics Technologies Corp.
- Dongkook Pharmaceutical Co., Ltd.
- Euroscreen S.A.
- Kissei Pharmaceutical Co., Ltd.
- Laboratoire HRA Pharma
- Repros Therapeutics Inc.
- Takeda Pharmaceutical Company Limited
For more information about this report visit http://www.researchandmarkets.com/research/xn2t6g/uterine_leiomyoma
Related Topics: Women’s
Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716